Vitamin C pharmacokinetics of plain and slow release formulations in smokers

Department of Clinical Pharmacology Q 7642, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Denmark.
Clinical Nutrition (Impact Factor: 3.94). 11/2004; 23(5):1043-50. DOI: 10.1016/j.clnu.2004.01.007
Source: PubMed

ABSTRACT Combination of the antioxidants ascorbic acid in slow release formulation and alpha-tocopherol can retard the progression of atherosclerosis. In order to determine if differences in formulation could explain some of the different results in the intervention trials we determined selected pharmacokinetics for two different formulations of ascorbic acid together with alpha-tocopherol.
Single-blinded, randomised, placebo-controlled intervention study with 48 healthy men, aged 20-65 years, smoking > or = 5 cigarettes/day. Subjects received 250 mg plain release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate, 250 mg slow release ascorbic acid and 91 mg plain release d-alpha-tocopheryl acetate or placebo twice daily for 4 weeks. A series of blood samples were collected after administration of the first dose and repeated after 4 weeks of supplementation.
The fluctuation of ascorbic acid plasma concentrations decreased significantly (P = 0.003) after 4 weeks supplementation in the slow versus the plain release group.
This study shows that there were pharmacokinetic differences between plain and slow release formulations of ascorbic acid. However, these effects are small and unlikely to be of significant clinical importance.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to identify the cause of atypical shape of measured concentration-time profile in the peak area by one compartment open model with a lag time (Bateman function with a lag) after single dose oral administration of drug published in "Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Application" by Gabrielsson and Weiner (1997) and two concentration profiles after frequent sampling oral glucose tolerance test. Following the oral administration of 100 μg of substance A to human volunteer, frequent sampling was carried out and concentration-time profiles were obtained. Our hemodynamic circulatory structural model capable of parameters estimation of circulation and gastrointestinal subsystem to explain the plateau within the interval 40-100 min (substance A) and 15-30 min (glucose) of the measured concentration-time profile was developed. The mean residence time, the rate constants of absorption and elimination parameters of our model were calculated. Comparing to the Bateman function, our results demonstrate better approximation of the substance A and glucose concentration-time profile and estimation of absorption rate constant by our structural model. Obtained model results indicate that the atypical shape of measured concentration-time profile of single dose oral administration of drug was probably caused by the gastrointestinal and circulation system with deep compartment. This applies to the substances with high coefficient of absorption.
    Indian Journal of Pharmaceutical Sciences 03/2013; 75(2):171-7. · 0.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significance: Despite continuous advances in the prevention of cardiovascular disease, critical issues associated with an unhealthy lifestyle remain an increasing cause of morbidity and mortality in industrialized countries. Recent Advances: A growing body of literature supports a specific role for vitamin C in a number of reactions associated with vascular function and control including e.g. nitric oxide bioavailability, lipid metabolism, and vascular integrity. Critical Issues: A large body of epidemiological evidence supports a relationship between poor vitamin C status and increased risk of developing cardiovascular disease, and the prevalence of deficiency continues to be around 10-20% of the general Western population although this problem could easily and cheaply be solved by supplementation. However, large intervention studies using vitamin C have not found a beneficial effect of supplementation. This review outlines the proposed mechanism by which vitamin C deficiency worsens cardiovascular disease progression. In addition, it discusses problems with the currently available literature, including the discrepancies between the large intervention studies and the experimental and epidemiological literature. Future Directions: Increased insight into vitamin C deficiency mediated cardiovascular disease progression will enable the design of future randomized controlled trials that are better suited to test the efficacy of vitamin C in disease prevention as well as the identification of high risk individuals that could possibly benefit from supplementation.
    Antioxidants & Redox Signaling 05/2013; DOI:10.1089/ars.2013.5382 · 7.67 Impact Factor
  • Source


Available from